National Research (NASDAQ:NRC) Stock Passes Above 200 Day Moving Average – What’s Next?

National Research Corporation (NASDAQ:NRC)’s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $14.91 and traded as high as $18.01. National Research shares last traded at $18.00, with a volume of 69,368 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of National Research in a research note on Monday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, National Research presently has an average rating of “Sell”.

National Research Stock Up 1.1%

The company has a debt-to-equity ratio of 5.31, a quick ratio of 0.53 and a current ratio of 0.53. The stock has a market cap of $422.38 million, a price-to-earnings ratio of 26.63 and a beta of 0.45. The business’s 50 day moving average is $14.81 and its 200 day moving average is $14.97.

National Research (NASDAQ:NRC) last released its earnings results on Monday, October 27th. The company reported $0.23 earnings per share (EPS) for the quarter. National Research had a return on equity of 98.26% and a net margin of 11.76%.The company had revenue of $34.61 million during the quarter.

National Research Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 9th. Investors of record on Friday, December 26th will be given a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, December 26th. This is a boost from National Research’s previous quarterly dividend of $0.12. This represents a $0.64 annualized dividend and a yield of 3.4%. National Research’s payout ratio is 68.57%.

Institutional Investors Weigh In On National Research

Several institutional investors and hedge funds have recently modified their holdings of the business. Los Angeles Capital Management LLC bought a new position in shares of National Research in the 2nd quarter valued at approximately $403,000. QV Investors Inc. grew its holdings in National Research by 7.6% during the second quarter. QV Investors Inc. now owns 381,310 shares of the company’s stock valued at $6,406,000 after purchasing an additional 26,950 shares during the last quarter. Vanguard Personalized Indexing Management LLC acquired a new position in National Research during the second quarter valued at approximately $444,000. CWM LLC raised its position in shares of National Research by 192.0% in the second quarter. CWM LLC now owns 6,847 shares of the company’s stock valued at $115,000 after purchasing an additional 4,502 shares during the period. Finally, Rhumbline Advisers lifted its stake in shares of National Research by 4.5% in the first quarter. Rhumbline Advisers now owns 22,204 shares of the company’s stock worth $284,000 after buying an additional 946 shares during the last quarter. Institutional investors and hedge funds own 47.26% of the company’s stock.

About National Research

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.